The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects with Advanced Solid Tumors
- collapse A Phase 2 Randomized Open-Label Study of MEDI-551 in Adults with Relapsed or Refractory DLBCL
- collapse A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.
- collapse A Phase 2 Open-Label Study of MEDI-551 and Bendamustine vs. Rituximab and Bendamustine in Adults with Relapsed or Refractory CLL
- collapse A Phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Who Responded to Gefitinib in 1st Line and Progressed After 2nd Line Chemotherapy.
- collapse A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
- collapse A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL)
- collapse A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults with Refractory CD22+ Acute Lymphoblastick Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL)
- collapse A Phase I Open-Label Study to Assess the Safety and Tolerability of AZD2281(KU-0059436) in Combination with carboplatin (phase I), or in combination with a carboplatin/paclitaxel doublet (phase IIa), or in combination with paclitaxel (phase IIb) in the Treatment of Patients with Advanced Solid Tumours.
- collapse A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
